Welcome to our dedicated page for NIKA PHARMACEUTICALS SEC filings (Ticker: NIKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NIKA PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NIKA PHARMACEUTICALS's regulatory disclosures and financial reporting.
Nika Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2026 and continues to operate in a pre-commercial stage. For the quarter, the company recorded a net loss of $19,694, bringing the six‑month net loss to $33,054 and the accumulated deficit to $9,037,063.
Total assets were $9,942, consisting almost entirely of cash and prepaid expenses, against total liabilities of $340,624, resulting in a stockholders’ deficit of $330,682 as of June 30, 2026. The company relied on $22,000 of non‑interest‑bearing related‑party loans to fund operating cash outflows of $20,957 in the first half of 2026.
Management states that recurring losses, no revenue, and dependence on related‑party financing raise substantial doubt about the ability to continue as a going concern. The report also identifies material weaknesses in internal control, including the lack of an audit committee and limited separation of duties, though no restatement was required for a timing error in prepaid expense amortization.
Nika Pharmaceuticals, Inc. reported another development-stage quarter with no revenue and a small net loss of $13,359 for the three months ended March 31, 2026, similar to the $12,945 loss a year earlier. Cash was very limited at $1,530, compared with current liabilities of $331,624, and the accumulated deficit reached $9,017,368, leading management to state there is substantial doubt about the company’s ability to continue as a going concern.
The business remains funded by non‑interest‑bearing, due‑on‑demand loans from related parties, including $13,000 advanced in the quarter. Nika continues to build its pharmaceutical platform through exclusive rights agreements, a controlling interest in Nika Europe Ltd., and a production agreement for ITV‑1 once a new factory in Bulgaria is completed. Internal controls over financial reporting were deemed ineffective due to a lack of an audit committee and limited separation of duties.
Nika Pharmaceuticals, Inc. filed its annual report detailing continued development-stage operations with no revenue and a small net loss of $76,398 for the year ended December 31, 2025, improving from a $95,792 loss in 2024. Operating expenses were modest at $76,398, mainly general and administrative and professional fees.
The balance sheet remains very thin, with cash of $1,889, current assets of $20,996, and a working capital and stockholders’ deficit of $297,628. Related parties funded operations via non‑interest‑bearing, on‑demand loans totaling $318,624. Accumulated deficit reached $9,004,009, and the auditor issued a going concern emphasis citing substantial doubt about the company’s ability to continue without new financing.
The company advanced multiple exclusive rights and cooperation agreements around Thymus Nuclear Glycoprotein, the IPF platform, and several dietary supplements, and completed a common control merger with Nika BioTechnology, Inc., resulting in 1,047,549,224 common shares and 15,000,000 preferred shares outstanding. All preferred shares carry 1,000 votes each, giving CEO Dimitar Slavchev Savov effective voting control. Nika trades on the OTCQB under the symbol NIKA and qualifies as an emerging growth company, using reduced disclosure and extended accounting standard transition periods. Internal control over financial reporting was deemed ineffective, with material weaknesses including lack of an audit committee and segregation of duties.
Nika Pharmaceuticals, Inc. filed its Q3 2025 report, showing no revenue and a net loss of $7,999 for the quarter ended September 30, 2025 (nine months: $39,309). Cash was $6,287 and current liabilities were $284,164, resulting in a stockholders’ deficit of $260,539. The company disclosed “substantial doubt” about its ability to continue as a going concern.
Operations were funded by related-party advances, including $45,000 during the nine months. At quarter-end, amounts due included $45,000 to Nika Europe, $205,164 to the CEO, and $34,000 to Nika Pharmaceuticals LTD, all non‑interest bearing and due on demand. The company continued accounting for a common control merger and issued 13,230,000 of the 204,205,027 common shares to be issued under that agreement. Common shares outstanding were 1,039,836,001 as of November 7, 2025.
Disclosure controls were deemed not effective due to a lack of an audit committee and separation of duties. The report also notes a production agreement with Nika Europe for ITV‑1 with a framework price of $580 per set, tied to factory completion.